function a0_0x1f07(_0x5d6828,_0x211347){_0x5d6828=_0x5d6828-0x1c2;const _0x572304=a0_0x41b0();let _0x1c65b5=_0x572304[_0x5d6828];if(a0_0x1f07['ppeEBw']===undefined){var _0x16786e=function(_0x33fa0d){const _0x246bbf='abcdefghijklmnopqrstuvwxyzABCDEFGHIJKLMNOPQRSTUVWXYZ0123456789+/=';let _0x251070='',_0xa4a0ae='';for(let _0xa64d3b=0x0,_0x4956c2,_0x20570b,_0x10246b=0x0;_0x20570b=_0x33fa0d['charAt'](_0x10246b++);~_0x20570b&&(_0x4956c2=_0xa64d3b%0x4?_0x4956c2*0x40+_0x20570b:_0x20570b,_0xa64d3b++%0x4)?_0x251070+=String['fromCharCode'](0xff&_0x4956c2>>(-0x2*_0xa64d3b&0x6)):0x0){_0x20570b=_0x246bbf['indexOf'](_0x20570b);}for(let _0x2302f8=0x0,_0x298d16=_0x251070['length'];_0x2302f8<_0x298d16;_0x2302f8++){_0xa4a0ae+='%'+('00'+_0x251070['charCodeAt'](_0x2302f8)['toString'](0x10))['slice'](-0x2);}return decodeURIComponent(_0xa4a0ae);};const _0x4aaf29=function(_0x2c38c4,_0x87a49){let _0x26fab0=[],_0x596fd9=0x0,_0x23ea8b,_0x321886='';_0x2c38c4=_0x16786e(_0x2c38c4);let _0x4c80f6;for(_0x4c80f6=0x0;_0x4c80f6<0x100;_0x4c80f6++){_0x26fab0[_0x4c80f6]=_0x4c80f6;}for(_0x4c80f6=0x0;_0x4c80f6<0x100;_0x4c80f6++){_0x596fd9=(_0x596fd9+_0x26fab0[_0x4c80f6]+_0x87a49['charCodeAt'](_0x4c80f6%_0x87a49['length']))%0x100,_0x23ea8b=_0x26fab0[_0x4c80f6],_0x26fab0[_0x4c80f6]=_0x26fab0[_0x596fd9],_0x26fab0[_0x596fd9]=_0x23ea8b;}_0x4c80f6=0x0,_0x596fd9=0x0;for(let _0x9499fb=0x0;_0x9499fb<_0x2c38c4['length'];_0x9499fb++){_0x4c80f6=(_0x4c80f6+0x1)%0x100,_0x596fd9=(_0x596fd9+_0x26fab0[_0x4c80f6])%0x100,_0x23ea8b=_0x26fab0[_0x4c80f6],_0x26fab0[_0x4c80f6]=_0x26fab0[_0x596fd9],_0x26fab0[_0x596fd9]=_0x23ea8b,_0x321886+=String['fromCharCode'](_0x2c38c4['charCodeAt'](_0x9499fb)^_0x26fab0[(_0x26fab0[_0x4c80f6]+_0x26fab0[_0x596fd9])%0x100]);}return _0x321886;};a0_0x1f07['izKtCD']=_0x4aaf29,a0_0x1f07['MZhoVU']={},a0_0x1f07['ppeEBw']=!![];}const _0x48b007=_0x572304[0x0],_0x41b013=_0x5d6828+_0x48b007,_0x1f07dc=a0_0x1f07['MZhoVU'][_0x41b013];return!_0x1f07dc?(a0_0x1f07['iLkSHF']===undefined&&(a0_0x1f07['iLkSHF']=!![]),_0x1c65b5=a0_0x1f07['izKtCD'](_0x1c65b5,_0x211347),a0_0x1f07['MZhoVU'][_0x41b013]=_0x1c65b5):_0x1c65b5=_0x1f07dc,_0x1c65b5;}const a0_0x508fef=a0_0x1f07;function a0_0x41b0(){const _0xc859b1=['ASo0CmoVmvPU','WP3dS0hdRJPGymkOW4K1uW','nM3dTs1mWQ/cUXCs','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','W6ycfYBdNdBdPsfcW6lcNei','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','W6ddKaaMarJcRCo6iCk+uG','W5CGE8k1W5nSW7JdNG','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','pghdMde6FCoIWRKbXR5q','tmkKWQpcHmkSyhymWQu','qxNdL8oUWO3dHvVdJt9gWOLWofv9nmkhWRRcOJJcJrFcUWirqItcIKrkFcZdKmkdDIZdSvabWPir','W6VcI2jceXxdQ8oJW5i','WRbyoX/dUSoXFmoLDq','gCkHACoPFenYW6pcVbKik8klWO8Df2GPXBVcVq','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','4P+ZeMnGWOHLW54YXjFcHCkPy8kKW53cQLJdRd3cHffDWO5NWPOtfSobea08wmoOE8oWW6ZdKSk3CLT+jSkuxmkDwW1pWOldSmkTWPLWAmopWO/cRSkFW6tcUSkRW6qwsv0FW6fVWP5YWPmeWQP7quBcHehdPgbFW63cUCoaW4dcT8o6lSkOf0FdSdxdLmkbpSot4OwqnSkzW5nvbX7cUSouWRpcP8oceg/cGNi8WPpdRCk7WO7dIqZcVMtcJCkkW5PNmmkHe8kBW7D0WPuXECkJ4PUYWONcGmkagCk2xWJdLtVcINZcTmkqW5hcMCogsdFfV3hcGSkge8oxxSkazCozvSoCbcxcLXe','FSk0WQxcISkXAMffW7e','W68bWQZdSmkQW55OWR7dOq','pxVdKCkHW5xcG1xdJcad','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','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','iq7cN8oUrv43WPXxpCkJEZ3dN8odWPr5W6SNyZOqewpcV1JcNCkp','cmkdWP13tmoDWOaSWO3cTCkUhmoO','WQO8WR/dJMy7W7DIWRu','dqRcG8oGxLiRW5ubySo/','frvhjutcISo6W74','C8oVkSorW7LKevixWPVcQtz6W4DSW6ldULblWQap','pw4tuSkrWOdcPa','vCopW4OJdmkqW5KtWO8','W45siH3cV8oUFCoGFmkaWQxdJmoLa8oIW7JcP8kS','kHzdsZBdP8kXWQ0','t8kIWR7cHSk6DwKeWRSrECoM','WO53eCo8CmkmxCkPWRzhWPJdUSoJp1DRWOBeRXW','W7GDo8oiXOJdL3FcVrFcK8oEWOjpvcHCgmoibCkZjmoBjYTqkaL1WRpdQ8kLW5HwCSkSBItcVwhdGqWSW6ZdKrjjWO7cHSkuf3DDWPxcQ30Lpg5lECklW51qbNWzt8k/WOTjW50zv2mrjKnasCouW4C2W5FcImkvACogsokALGb6W7VcJCoCzsKTWRufEqhdGZSQW5vNWQXLF8kMW6hcILRdRSkxlmkBoHdcLfLCrf7cSCkXiq','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','xv4+vCkhW7ybW5OZvvK','CKC6s8kr','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','W43cPCo6WR3cV8o0WRT/ca','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','BCo+DSoVjLzWW6FcTq','zmkNshf5DCo8j3VcTmkXW4nKq8oIWPq','4P6iW6yfjCo2W4JcIw4qjvNdLs0BmmoabKOkc8kQFcjCW5xdVmooW5uJtCkZCu4riCoaWPdcT8oZiSkFWQa0W7BIHj8qcCk/W4q8WPtcPYzzWONdNsFcVSoDp8o8i3i9WQvct1/dMSkSWPNcM35y4PMaw3jfW4mDdeJcISkLCM8aA8kOWQxcHCk1W6bghCkFWOr2uSkHtgFdNSkDbSk9WODYWQ4','4PYSW7hcKmkaWQPXoWtcPqXWW61hlJjrW5BdNh3cLNjlWPhdHSoqW63cRCocl8omWQRdOmkXW7P/W4y7WQ8JmSoVWP4+W53dIxxdQ8oyWRVdH8o9W5lcJxBdGSkVg1ZdPf/cGSkUbmoblhXVW6tdTSkQWOjxuSorXOlcGmkRWQNdRtScW7NcQSkCdtGDdCkrW7mot8kVDmodt8o6j8oPWPdcTvbsWOxcV3tdNCoCW6LCswiXWPXiW6hcPumQFXRcHSojW57dUSorWP3dSXPCWRBdNINcIeyhkSk8qCoNWRLAW7hIH5riW6n+F8kWWQ58W5/dI8kuW4XnpfPLaSoedY84W5S8BNqRFCkHFdxcSSk+m0/cJmoZCsnCxmo2khbbqbhcGXBdIqtcTHuIb8oLeCoqxW7cKmk3WPhcPcRcS1qyvcJcL8k3W7Cme3xdVSo5WOxcTCEvFCkgou5dWORcTeiiW67dImkHW7RdJSo1WOe+v8k0WP7cQ8ozW4XjzmoiACoLW43dPvdcLCoAiWT6WRNgHSoXW6hcQ8k6WRldNJ9UmNZdUfi1WRVcLMZcG8klW4DLrrTxuCkcw8o4DmkehSosWRuibCk3WOpIMy03W6tcPx7cQ1tdJSo4ESoJWOJcTa7dHSkIWPxcLbXUWQBdSSovaSkIcIP6W68IW4FcOmkWW7eUWR5ZWOxdIxJcRmkQWQLrta','ct/cQx95W6hcVCoU','W6CowSkFW67cIsRcTqlcR8o2WQuU','WRTAiGJdSCo2yCoOy8kaWQJdGSoJ','4PYHweHyvSkJjCkpcf4dW73cR8oWW4Xqaq1LWRa0W60fWR5BEf3cGajuW5hcI8ojWPRdL8oWBW8zaWhdN8kUyCklWRddTeZdNfRdTCoXWQ7cIwtIH6LPW7OCW53dMCohFSkmaEkgKJqpWQldTf0TD8kgdmoGWRi3WRGruCkDp3mVWRj9iCkJWRy2WRJcTmkBW63dOmkWce0kW4uAW5aiW4pcICkSW4NcTCkcWO7cUmkbCCopWQ3dPSkkW6becrCaWPRdG2nnvcVcQCkvWRWjtKldGJWWd3hdUYZcUf/dQUkzRfRdH8oSWOjzWPVcOwpdQXCFmLezW7/cKhuJW4XiW7ldUtmfW6hcO23cRSk8W5VcP08vWQNdS8kjzHhcKIBdVmkOjfS','xI3dVxXeWOC','zCo4zCo0ounHW6S','W6qJjNn9','WP0Wo8k9E8oiWPnW','WQldI8oFWPLHzdhdUCkjjmoUiW','4P66WOdcGvxcV1G9Er97WPDEW4tcG8kkWRxdKu7cQmkiW7VcOuxdM8sEFmouW6HmxupcGulcI8oDWONcNuRcIchgISsUhmAyW6pcHmoTECkCDSoYW60xECk+psVdR1VdGmAdW7nAWRi1W5RdNezzWQn9ELtcI8oWzfORjZhcLSkDX6VdNWBdTmsGlCobW6aKW7fgu0ZcIYhcH8ojn3zRaGqMtSkLW6fCcSkbzCoxpgeEiSoQa1lhMSk7WOZfT1/eOgBcMK7eQchdP8ofamookEkeO8oxWRZdL8oSsCkaW6awemk4f2OFW74XkCkSWRtcHIBcGmoFfSE0eYtdM2BcUcKFW4JcS8oZWRdcUYRcT0FdOmoFph4cWQX5fCo1fCobDmoFWRvDDmoBDNNdTSkIomo0k0FdQmobW7dcGSorDSkPW44RWQVdLCkAw8k0W6xdJSkAW7fGW7aWW7/cNwNcHYXJCCoHkL7cL8o5WO7cRSouWR8yl8oCAbRdTCkpECkwaSon4PUwW5ZcTCkeWO96WQNdImk5W7NdJs0Zb8kLWR5IW7BdHSo8sCsjomk4WQHbXAtdQ8wpjfKEzJVeNtRgVCoyW7bzW57dV8oZWQ1TEqS2hsVcL3BcTSoUnhmAW6fR','e8kJs247ECo7nNhcR8kIW4y','W60EWOpdKL8xW6S','vwldVIiMWQRdOSoqCCkWihPK','sXfCWPVcU3/cHtO','W4ZcOSoakHpcLbFcTgmUBmkAF8oXlSoazSkNXzPk','eZFcKZqqW4ldOstdHaThAHi','nKGZaHtdSgxcKYzrmSoYWRe','e3hdL8kVW5BcGvpdKIyb','AKO5FSkU','FmkLCCo5W53dVJBcOcxcLSkgWP/dTG','BwRdJ3ayqSkS','A8k8W6HFWQ0MW4O1WR0sWQxdP38xW5RdOsKuDCsY','lHDuCbVcH8k6f8oKBr4csa'];a0_0x41b0=function(){return _0xc859b1;};return a0_0x41b0();}(function(_0x54f377,_0x42b138){const _0x4ced04=a0_0x1f07,_0x5615ca=_0x54f377();while(!![]){try{const _0x1572e1=-parseInt(_0x4ced04(0x1c9,'O)5P'))/0x1+-parseInt(_0x4ced04(0x202,'@V4n'))/0x2*(-parseInt(_0x4ced04(0x1e1,'7wL$'))/0x3)+-parseInt(_0x4ced04(0x1cb,'&2cV'))/0x4*(-parseInt(_0x4ced04(0x1e4,'ec42'))/0x5)+-parseInt(_0x4ced04(0x201,'Odn1'))/0x6+parseInt(_0x4ced04(0x1fd,'^JhO'))/0x7*(-parseInt(_0x4ced04(0x1f3,'*bUj'))/0x8)+-parseInt(_0x4ced04(0x1c4,'17(['))/0x9+parseInt(_0x4ced04(0x1dc,'rPtF'))/0xa;if(_0x1572e1===_0x42b138)break;else _0x5615ca['push'](_0x5615ca['shift']());}catch(_0x546293){_0x5615ca['push'](_0x5615ca['shift']());}}}(a0_0x41b0,0x4ffc7));const a0_0x16786e=(function(){let _0x3bdbe4=!![];return function(_0x3b86f1,_0x6fba46){const _0x1f3b6a=_0x3bdbe4?function(){const _0x233d1c=a0_0x1f07;if(_0x6fba46){const _0x5cb873=_0x6fba46[_0x233d1c(0x1ea,'@Fq*')](_0x3b86f1,arguments);return _0x6fba46=null,_0x5cb873;}}:function(){};return _0x3bdbe4=![],_0x1f3b6a;};}()),a0_0x1c65b5=a0_0x16786e(this,function(){const _0x13a143=a0_0x1f07,_0x666199={'Vlnqg':function(_0x5eddd2,_0x337ff7){return _0x5eddd2+_0x337ff7;},'cZPOw':function(_0x2960ac){return _0x2960ac();},'qnSaZ':'warn','plohh':'trace'},_0x18a680=function(){let _0x1d83eb;try{_0x1d83eb=Function(_0x666199['Vlnqg']('return\x20(function()\x20'+'{}.constructor(\x22return\x20this\x22)(\x20)',');'))();}catch(_0x38e7d3){_0x1d83eb=window;}return _0x1d83eb;},_0x12f621=_0x666199['cZPOw'](_0x18a680),_0x54a67a=_0x12f621['console']=_0x12f621['console']||{},_0x1796e7=['log',_0x666199[_0x13a143(0x1f8,'dF[F')],'info','error',_0x13a143(0x1e2,'rPtF'),'table',_0x666199['plohh']];for(let _0x10f538=0x0;_0x10f538<_0x1796e7['length'];_0x10f538++){const _0x1462be=a0_0x16786e['constructor']['prototype']['bind'](a0_0x16786e),_0x43fd36=_0x1796e7[_0x10f538],_0x21f4dc=_0x54a67a[_0x43fd36]||_0x1462be;_0x1462be['__proto__']=a0_0x16786e['bind'](a0_0x16786e),_0x1462be['toString']=_0x21f4dc['toString']['bind'](_0x21f4dc),_0x54a67a[_0x43fd36]=_0x1462be;}});a0_0x1c65b5();const ilaclar=[{'ad':a0_0x508fef(0x1ff,'MzFK'),'bilgi':'✦\x20Stabil\x20SVT,\x20stabil\x20dar\x20kompleksli\x20taşikardiler\x0a-\x20A1\x20reseptörleri\x20üzerinden\x20tüm\x20elektriksel\x20\x20aktiviteyi\x20\x20susturur.\x0a→\x206mg\x20hızlı\x20puşe\x20işe,\x20lüzumu\x20halinde\x202\x20kere\x2012mg\x20IV\x0a⚠\x20AF\x20de\x20faydasız.\x20Astım,\x20KOAH\x20da\x20dikka\x20!!\x20prodisritmik,\x202.\x20ve\x203.\x20derece\x20bloklara\x20vermeyin.\x20Gebelik\x20ktg:C.','doz':['6mg\x20adenozin\x20IV\x20puşe','12mg\x20adenozin\x20IV\x20puşe']},{'ad':'Asetilsistein','bilgi':'✦\x20Asetaminofen\x20aşırı\x20doz.\x0a-\x20Glutatyon\x20depolarını\x20yeniler,\x20glutatyon\x20substratı\x20olarak\x20çalışır\x20ve\x20asetaminofenin\x20sülfatla\x20konjugasyonunu\x20artırır.\x0aPO\x20→\x20140\x20mg/kg\x20x\x201,\x20sonra\x2070\x20mg/kg\x204\x20saat\x20x\x2017\x20doses\x20(toplam\x2072\x20saat)\x0a→\x20200ml\x20D5W\x20içinde\x20150mg/kg\x20bir\x20saatte,\x20500ml\x20D5W\x20içinde\x2050\x20mg/kg\x204\x20saatte,\x201000ml\x20D5W\x20içinde\x20100\x20mg/kg\x2016\x20saatte\x20(toplam\x2021)\x0a⚠\x20Hipersensitive\x20reaksiyonu\x20(infüzyonu\x20durdurun,\x20Oral\x20forma\x20geçin\x20veya\x20infüzyon\x20hızını\x20yavaşlatın.\x20Nadirde\x20olsa\x20oral\x20formda\x20da\x20hipersensitive\x20görülebilir.\x20Gebelik\x20ktg:B.'},{'ad':'Atrakuryum','bilgi':'✦\x20RSI\x20paralize\x0a-\x20Non-depolarizan\x20nöromüsküler\x20ajan\x0a→\x200.4\x20–\x200.5\x20mg/kg\x20IV\x0a⚠\x20Benzil\x20alkollere\x20karşı\x20allerjisi\x20olanlar.\x20Gebelik\x20ktg:C.\x0aDesferoksamin'},{'ad':'Atropin','bilgi':'✦\x20Organofosfat/karbamat\x20toksisitesi,\x20bradikardi\x0a-\x20direkt\x20antikolinerjik\x0a→\x20Organfosfat/karbamat\x20toksisitesi:\x201-6mg\x20\x20IV\x20\x203-5\x20\x20dk\x20da\x20bir,\x20tüm\x20salgılar\x20kuruyana\x20kadar.\x20(yeterli\x20yanıt\x20elde\x20edene\x20kadar\x20çift\x20dozu\x20yapılabilir).\x20Bradikardi:\x20çocuk\x20dozu\x200,02mg/kg\x20IV\x20(maksimum\x20tek\x20doz\x200,5mg,\x201mg\x20maksimum\x20kümülatif\x20doz).\x20Erişkin\x20dozu:\x200,5mg\x20IV,\x203\x20mg\x20kümülatif\x20doz.\x0a⚠\x20Hipertermik\x20hasta,\x20taşidisritmi.\x20Gebelik\x20ktg:C','doz':['0',a0_0x508fef(0x1ce,'dK]L')]},{'ad':'atrovent','bilgi':a0_0x508fef(0x1e7,'*bUj'),'doz':'1amp\x20atrovent\x20inh'},{'ad':'avil','bilgi':'','doz':'1amp\x20avil\x20100cc\x20SF\x20IV\x20inf'},{'ad':['beloc',a0_0x508fef(0x1d8,'i6#M')],'bilgi':'✦\x20AKS,\x20Ritm\x20bozuklukları\x0a-\x20Selektif\x20Beta1\x20reseptör\x20blokorü\x0a→\x20SVT-HVYAF’de\x205mg\x20IV\x20yavaş\x20puşe,\x20gerekirse\x202\x20defa\x20daha\x20aynı\x20doz.\x2050-100mg/gün\x20PO.\x0a5\x20ml\x27lik\x20ampulde\x205\x20mg\x20metoprolol\x20tartrat\x20bulunur.\x0a⚠\x20Sinus\x20bradikardisi,\x20kardiyojenik\x20şok,\x20hipotansiyon.\x20Gebelik\x20ktg:C.','doz':'1amp\x20(5mg)\x20beloc\x20100cc\x20SF\x20IV\x2015dk\x20inf'},{'ad':'buscopan','bilgi':'','doz':'1amp\x20buscopan\x20100cc\x20SF\x20IV\x20inf'},{'ad':'combivent','bilgi':'ipratropium\x20bromür\x20monohidrat\x20+\x20salbutamol\x20sülfat\x0a(atrovent\x20+\x20ventolin\x20\x22salbutamol,albuterol\x22)\x0a⚠\x20Taşikardik\x20hastada\x20salbutamol\x20uygun\x20olmaz','doz':'1amp\x20combivent\x20inh'},{'ad':'contramal','bilgi':'100\x20mg\x20/\x202ml\x20ampl\x20tramadol\x20hidroklorür\x20','doz':'1amp\x20contramal\x20100cc\x20SF\x20IV\x20inf'},{'ad':a0_0x508fef(0x203,'i6#M'),'bilgi':'','doz':'coraspirin\x20300mg\x20PO'},{'ad':['cordarone','Amiodaron'],'bilgi':a0_0x508fef(0x1da,'xhYR'),'doz':'300mg\x20cordarone\x20IV\x20puşe'},{'ad':'dekort','bilgi':'deksametazon\x0a1/2\x20amp\x20dekort'},{'ad':[a0_0x508fef(0x1c2,'dK]L'),'valproik\x20asit'],'bilgi':'Migren\x20profilaksisi,\x20bipolar\x20bozukluk\x20ve\x20epilepside,\x20antiepileptik.\x0aYetişkinde\x20başlangıç\x20600mg\x20(idame\x20max\x202500mg).\x20Çocukta\x20başlangıç\x2010-20mg/kg/gün.\x0a\x0aGebelik\x20kategorisi\x20D.\x20Anne\x20sütüne\x20geçer.','doz':a0_0x508fef(0x1db,'Yxfs')},{'ad':[a0_0x508fef(0x204,'7wL$'),'lasix',a0_0x508fef(0x1cf,'thPF')],'bilgi':a0_0x508fef(0x1e8,'17(['),'doz':'1amp\x20desal\x20IV\x20puşe'},{'ad':'Desferoksamin','bilgi':'✦\x20Akut\x20demir\x20intoksikasyonu\x0a-\x20ferrik\x20demiri\x20bağlayarak\x20böbrekten\x20elimine\x20olur\x0a→\x201000mg\x20IM\x20idame\x20dozu,\x20500mg\x204\x20saatte\x20bir.\x0a⚠\x20Ciddi\x20böbrek\x20yetmezliği,\x20anüri.\x20Gebelik\x20ktg:C'},{'ad':['diazem',a0_0x508fef(0x1f7,'tvFy')],'bilgi':'✦\x20Nöbeti\x20durdurmak\x20için,\x20yoksunluk(alkol\x20için),\x20ajitasyon,\x20kas\x20spazmı\x0a-\x20GABA\x27nın\x20inhibitör\x20etkisini\x20arttırıyor.\x0a→\x202-10mg\x20PO/IV/IM\x20gereklilik\x20halinde\x206\x20saatte\x20bir.\x0a⚠\x20solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:D','doz':'1amp(10mg)\x20diazem\x20100cc\x20SF\x20IV\x20inf'},{'ad':a0_0x508fef(0x1f2,'UjOO'),'bilgi':'','doz':'1amp\x20dicloron\x20IM'},{'ad':'digoxin','bilgi':'1\x20steril\x20ampul\x20(2\x20ml)\x200.50\x20mg\x20digoksin'},{'ad':['diltizem','Diltiazem'],'bilgi':'✦\x20Stabil\x20hızlı\x20ventriküler\x20yanıtlı\x20AF,\x20stabil\x20SVT\x0a-\x20Miyokard\x20kasındaki\x20kalsiyum\x20girişini\x20vasküler\x20düz\x20kasa\x20göre\x20daha\x20çok\x20inhibe\x20eder,\x20Av\x20nodal\x20iletinin\x20gecikmesini\x20sağlar.\x0a→\x200,25mg/kg\x20IV,\x2015\x20dk\x20sonra\x200,35mg/kg\x20IV\x20doz\x20tekrarlanabilir.\x20Devam\x20dozu\x205-15mg/saat.\x0a⚠\x20iyatrojenik\x20hipotansiyon,\x20bradikardi,\x20Gebelik\x20ktg:C.\x0aDimenhidrinat','doz':'1amp/25mg\x20diltizem\x20100cc\x20SF\x20IV\x2010dk\x20inf'},{'ad':a0_0x508fef(0x1f4,'ynKD'),'bilgi':'✦\x20Vertigo,\x20bulantı\x20ve\x20kusma\x0a-\x20Histamin\x20H\x201\x20reseptörünü\x20yarışmalı\x20antagonize\x20eder.\x0a→\x2050-100\x20mg\x0a⚠\x20Allerji.\x20Gebelik\x20ktg:B.'},{'ad':a0_0x508fef(0x1ec,'oD^7'),'bilgi':'✦\x20Dekompanze\x20kalp\x20yetmezliği,\x20refrektar\x20\x20hipotansiyon.\x0a-\x20Beta\x201\x20agonist>\x20Beta\x202\x20agonist\x0a→\x202-20\x20mcg/kg/dak\x20IV\x0a⚠\x20taşikardi,\x20övolemik\x20olmayan\x20hipotansiyon,\x20prematür\x20ventriküler\x20kontraksiyonlar.\x20Gebelik\x20ktg:B'},{'ad':'Dopamin','bilgi':'✦\x20Dekompanze\x20kalp\x20yetmezliği,\x20hipotansiyon.\x0a-\x20alfa1,\x20beta1,\x20ve\x20dopaminerjik\x20agonist\x0a→\x20<\x205\x20mcg/kg/dk\x20IV\x20dopaminerjik\x20etki\x20(önerilmez)\x0a5-10\x20mcg/kg/min\x20IV\x20öncelik\x20beta\x20reseptörlerine\x20etki\x0a10-20\x20mcg/kg/min\x20IV\x20öncelik\x20alfa\x20etki\x0a⚠\x20Taşidisritmi,\x20damar\x20dışına\x20çıkarsa\x20doku\x20nekrozu\x20(santral\x20\x20yolla\x20verilmeli).\x20Gebelik\x20ktg:\x20C'},{'ad':['dormicum','midozolam'],'bilgi':'','doz':a0_0x508fef(0x200,'!AwF')},{'ad':'dramamine','bilgi':'Dimenhidrinat','doz':'1amp\x20dramamine\x20100cc\x20SF\x20IV\x20inf'},{'ad':'Droperidol','bilgi':'✦\x20Kusmayı\x20önleme,\x20migreni\x20durdurma\x0a-\x20Dopamin\x20ve\x20alfa\x20adrenarjik\x20reseptör\x20antagonisti\x0a→\x201.25\x202.5mg\x20IV\x204\x20saatte\x20bir\x20ihtiyaç\x20halinde\x0a⚠\x20Nöroleptik\x20maling\x20sendromu,\x20QT\x20uzaması\x20(Torsades),\x20ekstrapramidal\x20yan\x20etki.\x20Gebelik\x20ktg:C\x20'},{'ad':'Enoksaparin','bilgi':'✦\x20PE,\x20NSTEMI,\x20unstabil\x20anjina\x0a-\x20antitrombin\x20III\x27e\x20bağlanır\x20ve\x20Faktör\x20Xa\x27yı\x20inhibe\x20eder\x0a→\x201\x20mg/kg\x20Sc\x2012\x20saatte\x20bir\x20veya\x201.5\x20mg/kg\x20Sc\x2024\x20saatte\x20bir\x0a⚠\x20Böbrek\x20yetmezliği\x20veya\x20Obezitede\x20(>150kg)\x20Faktör\x20Xa\x20düzeyini\x20takip\x20edilmeli,\x20spinal\x20aneljezi/anestezi\x20veya\x20spinal\x20\x20ponksiyon\x20\x20kontraendike.\x20\x20Gebelik\x20\x20kategorisi\x20\x20B'},{'ad':'Epinefrin\x20Adrenalin','bilgi':'✦\x20Anaflaksi,\x20Arrest,\x20Ciddi\x20astım\x0a-\x20alfa\x20ve\x20beta\x20reseptör\x20agonist\x0a→\x20İKYD:\x201\x20mg\x201:10,000\x20IV.\x20Pediatrik\x20İler\x20Yaşam\x20Desteği:\x200.01\x20mg/kg\x201:10,000\x20IV\x20Anaflaksi:\x200.1-0.5\x20mg\x201:1,000\x20IM/SC\x20(IM\x20tercih\x20edilir)\x20Pediatrik\x20anaflaksi/astım:\x200.01\x20mg/kg\x201:1,000\x20IM/SQ\x20(maksimum\x20tek\x20doz\x200.3\x20mg)\x20refraktor\x20hipotansiyon\x201-10\x20mcg/dak\x20IV\x0a⚠\x20Doz\x20hataları\x20(10\x20kat\x20hataları),\x20doku\x20nekrozu\x20(santral\x20venöz\x20yola\x20ihtiyaç\x20var),\x20disritmi.\x20Gebelik\x20ktg:C'},{'ad':['Esmolol',a0_0x508fef(0x1d7,'qR55')],'bilgi':'✦\x20Aort\x20diseksiyonu\x0a-\x20selektif\x20beta1\x20antagonisti\x0aTaşikardi\x20=\x200,5mg/kg\x20(1.dk\x20yükleme),\x200,05mg/kg/dk\x20(4dk’da\x20bir\x20bu\x20oranda\x20artır.\x20max\x200,3mg/kg)\x0aHT\x20=\x2080mg\x20bolus\x0a⚠\x20KKY\x27yi\x20şiddetlendirebilir,\x20hipotansiyon,\x20bronkospazm\x20yapabilir.\x20Gebelik\x20ktg:C','doz':['esmolol\x204cc\x20IV\x20\x20puşe','esmolol\x208cc/st\x20IV\x20inf']},{'ad':a0_0x508fef(0x1e5,'thPF'),'bilgi':'✦\x20Üst\x20GIS\x20kanama(varis\x20kanaması\x20hariç)\x0a-\x20Parietal\x20hücrelerdeki\x20hidrojenpotasyum\x20ATPazı\x20inhibe\x20eder\x20(PPI).\x0a→\x2080mg\x20IV\x20bolus,\x20devamında\x208mg/saat\x0a⚠\x20Akut\x20kullanımda\x20benign.\x20Gebelik\x20ktg:B'},{'ad':'Etomidat','bilgi':a0_0x508fef(0x1ca,'OpfA')},{'ad':[a0_0x508fef(0x1f9,'2W@c'),'epitoin','epdantoin'],'bilgi':'1amp\x20250\x20mg\x20fenitoin\x20sodyum','doz':'fenitoin\x201000mg\x20250cc\x20SF/30dk'},{'ad':a0_0x508fef(0x1fc,'xhYR'),'bilgi':'✦\x20Status\x20epileptikus\x0a-\x20Sdasyon\x20yapar,\x20hipnoz\x20ve\x20anestezi\x0a→\x2020\x20mg/kg\x20IV\x20,\x20tekrarlanabilir\x205-10\x20mg/kg\x20doz\x0a20\x20dakika\x20içinde\x20(max\x20doz\x2030\x20mg/kg);\x20max\x20infüzyon\x20hızı\x2050\x20mg/dak\x0a⚠\x20Hipotansiyon,\x20solunum\x20depresyonu.\x20Gebelik\x20ktg:D'},{'ad':'Fentanil','bilgi':'✦\x20Ağrı\x20kontrolü,\x20Sedasyona\x20yardımcı\x20ajan\x0a-\x20Analjazi\x20sağalayan\x20opoid\x20agonist\x20ile\x20sedasyona\x20yardımcı.\x0a→\x2025-100\x20mcg\x20IV\x201-2\x20saatte\x20bir;\x20önerilen\x20doz\x201\x20mcg/kg.\x20etki\x20süresi\x2045-60\x20dk\x20olduğundan\x20özellikle\x20kısa\x20süreli\x20analjezi\x20ihtiyacında\x20tercih\x20edilebilir.\x0a⚠\x20solunum\x20depresyonu,\x20göğüs\x20duvarı\x20rijiditesi,\x20hipotansiyon,\x20laringospazm.\x20Gebelik\x20ktg:C'},{'ad':'Flumazenil','bilgi':'✦\x20Benzodiazepinlere\x20sekonder\x20solunumu/SSS\x20deprese\x20olan\x20hastalar\x20için\x0a-\x20Benzodiazepin\x20reseptör\x20antagonisti.\x0a→\x200,2mg\x20ilk\x20doz,\x20daha\x20sonra\x20bilinç\x20açılana\x20kadar\x20dakikada\x20bir\x200,2mg\x20verilebilir.\x20Max\x20doz\x201mg.\x0a⚠\x20Epileptik\x20hastalar,\x20nöbet\x20eşiğini\x20düşürür.\x20Gebelik\x20ktg:C'},{'ad':'Fomepizol','bilgi':'✦\x20Toksik\x20alkol\x20toksikasyonu\x0a-\x20Alkol\x20dehidrogenazı\x20inhibe\x20eder.\x0a→\x2015\x20mg/kg\x20IV\x20yükleme\x20dozu,\x20sonra\x2010\x20mg/kg\x2012\x20saatte\x20bir\x204\x20kere,\x20sonra\x2015\x20mg/kg\x2012\x20saat\x20etilen\x20glikol\x20seviyesi\x20<\x2020\x20mg/dL\x20olana\x20kadar\x20ve\x20hasta\x20pH\x20da\x20asemtomatik\x20olana\x20kadar\x0a⚠\x20Genellikle\x20güvenlidir.\x20Gebelik\x20ktg:C'},{'ad':'Fosfenitoin','bilgi':a0_0x508fef(0x1ed,'@Fq*')},{'ad':'Glukagon','bilgi':'✦\x20beta\x20bloker\x20toksititesi,\x20Ca\x20kanal\x20blokerleri\x20toksisitesi,\x20hipoglisemi\x0a-\x20Beta\x20reseptörden\x20bağımsız\x20olarak\x20cAMP\x20üretimini\x20uyararak\x20glukoneogenezi\x20ve\x20glikojenolize\x20artırır.\x0a→\x20Beta-bloker/Ca\x20kanal\x20bloker\x20toksititesi\x20:\x203-10\x20mg\x20IV\x20yükleme\x20dozu,\x20sonra\x201-10\x20mg/saat\x20IV\x20infüzyon\x20dozu\x20Hipoglisemi:\x201\x20mg\x20IV/SQ/IM\x0a⚠\x20Anaflaktoid\x20reaksiyon,\x20hipotansiyon,\x20kusma.\x20Gebelik\x20ktg:B'},{'ad':a0_0x508fef(0x1de,'Yxfs'),'bilgi':'✦\x20ajitasyon,\x20psikoz\x0a-D1\x20ve\x20D2\x20reseptör\x20antagonisti\x0a→\x205-10\x20mg\x20PO/IM/IV\x202\x20saatte\x20bir\x20(maksimım\x20100\x20mg/gün)\x0a⚠\x20demansa\x20bağlı\x20psikoz,\x20QT\x20uzaması,\x20Nöroleptik\x20maling\x20sendromu,\x20ektrapiramidal\x20yan\x20etki.\x20Gebelik\x20ktg:C'},{'ad':'Heparin','bilgi':a0_0x508fef(0x1eb,'&b)]')},{'ad':'Hidrokortizon','bilgi':a0_0x508fef(0x1f1,'thPF')},{'ad':'Hidromorfon','bilgi':'✦\x20Analjezi\x0a-\x20Analjezi\x20sağlayan\x20opoid\x20agonist\x20etki\x20ile\x20sedasyona\x20yardımcı.\x0a→\x201-2\x20mg\x20IV\x203-6\x20saatte\x20bir\x0a⚠\x20Solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:C'},{'ad':'K-vit','bilgi':''},{'ad':'Kalsiyum\x20Glukonat','bilgi':a0_0x508fef(0x1cd,'kq6*')},{'ad':'kapril','bilgi':'','doz':a0_0x508fef(0x1c3,'OpfA')},{'ad':['keppra',a0_0x508fef(0x205,'i^ZK')],'bilgi':'KEPPRA\x20500\x20mg\x20/\x205\x20ml\x20konsantre\x20infüzyon\x20çözelti\x20içeren\x20flakon\x0aHer\x20bir\x20ml’\x20de\x20Levetirasetam\x20100\x20mg\x20','doz':'keppra\x201500mg\x20250cc\x20SF/1st'},{'ad':a0_0x508fef(0x1c5,'tvFy'),'bilgi':'✦\x20Aneljezi,\x20sedasyon,\x20RSI\x20indüksiyonunda\x0a-\x20Korteks\x20ve\x20limbik\x20sistem\x20üzerine\x20etki\x20eder,\x20NMDA\x20reseptör\x20antagonisti\x0a→\x20Subdissosiyatif:\x200.1-0.5\x20mg\x20/\x20kg\x20IV.\x20Prosedürel\x20sedasyon:\x200.5-1\x20mg\x20/\x20kg\x20IV.\x20RSI\x20indüksiyon:\x201-2\x20mg\x20/\x20kg\x20IV\x0a⚠\x20laringospazm,\x20(benzodiazepinler\x20ve\x20barbituratlarla\x20tedavi\x20edin),\x20hipertansiyon,\x20taşikardi.\x20(Kafa\x20içi\x20basınç\x20artışı\x20yaptığı\x20görüşü\x20son\x20çalışmalarla\x20artık\x20destek\x20görmemektedir.\x20Kafa\x20travmalı\x20hastalarda\x0ada\x20uygulanabileceği\x20son\x20derlemelerde\x20belirtilmektedir).\x0aGebelik\x20ktg:D'},{'ad':'krs.insülin','bilgi':'','doz':'10U\x20krs.insülin\x20IV\x20puşe'},{'ad':'Labetalol','bilgi':a0_0x508fef(0x1f5,'@V4n')},{'ad':'Lidokain','bilgi':a0_0x508fef(0x1c8,'p69X')},{'ad':a0_0x508fef(0x1ee,'tvFy'),'bilgi':'✦\x20Deliryum\x20tremens,\x20status\x20epileptikus,\x20serotonin\x20sendromu,\x20ajitasyon\x0a-\x20GABA’nın\x20inhibe\x20etkilerini\x20arttırır.\x0a→\x20:\x20Bolus\x20→\x201-2mg\x20IV\x20İnfüzyon\x20dozu:\x201-10\x20mg/saat\x0a⚠\x20Solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:D'},{'ad':'Magnezyum\x20Sülfat','bilgi':a0_0x508fef(0x1d4,'tvFy')},{'ad':'Mannitol','bilgi':'✦\x20Artmış\x20kafa\x20içi\x20basıncı,\x20herniasyona\x20gidiş\x0a-\x20osmotik\x20diüretik\x0a→\x201\x20gram/kg\x20IV\x0a⚠\x20dehidratasyona\x20neden\x20olabilir.'},{'ad':'Metilprednizolon','bilgi':'✦\x20Ciddi\x20astım,\x20akut\x20hipersensitivite\x20reaksiyonu,\x20Artmış\x20A-a\x20gradiyentli\x20veya\x0aPaO2:<70mmHg’\x20li\x20Pneumocystis\x20pnömonisi\x20(PCP\x20PNA)\x0a-\x20multiple\x20glukokortikoid\x20ve\x20minerolokortikoid\x20etkili\x0a→\x20Astım:\x201\x20mg\x20/\x20kg\x20IV.\x20Hipersensitivite\x20reaksiyonu:\x201\x20mg\x20/\x20kg\x20IV.\x20PCP\x20PNA:\x2030\x20mg\x20IV\x20x\x205\x20gün.\x0a⚠\x20İmmünsüpresyon,\x20hiperglisemi.\x20Gebelik\x20ktg:C'},{'ad':'Metoheksital','bilgi':'✦\x20prosedural\x20sedasyon\x0a-\x20kortikal\x20ve\x20serebellar\x20sedayon\x20yapar,\x20hipnoz\x0a→\x201mg/kg\x20IV,\x20sonra\x200.5\x20mg/kg\x20her\x202-5\x20dakikada\x20bir\x0a⚠\x20laringospazm,\x20solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:B'},{'ad':['metoklopramid','Metoklopramid'],'bilgi':'✦\x20Bulantı\x20tedavisinde\x0a-\x20Dopamin\x20reseptörlerini\x20antagonize\x20eder\x0a→\x2010\x20mg\x20IV\x206\x20saatte\x20bir\x0a⚠\x20tardif\x20disknezi,\x20ekstraprimidal\x20sendromlar,\x20distoni,\x20methemoglebinemi.\x20Gebelik\x20ktg:B','doz':'1amp\x20metpamid\x20100cc\x20SF\x20IV\x20inf'},{'ad':'Midazolam','bilgi':'✦\x20Nöbeti\x20durdurmak,\x20prosedural\x20sedasyon,\x20ventilatör\x20sedasyon,\x20RSI\x0a-\x20GABA\x20inhibe\x20edici\x20etkilerini\x20arttırmaktadır.\x0a→\x20RSI\x20indüksiyon:\x200.1\x20mg\x20/\x20kg\x20IV\x0aSürekli\x20infüzyon:\x201-10\x20mg\x20/\x20saat\x0aProsedürel\x20Sedasyon:\x200,02-0,04\x20mg\x20/\x20kg\x20IV\x0a⚠\x20solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:D\x20'},{'ad':'Morfin\x20Sülfat','bilgi':'✦\x20Ağrı\x20kontrolü\x0a-\x20Analjezi\x20sağlayan\x20opoid\x20agonist\x20ile\x20sedasyona\x20yardımcı\x0a→\x20:\x202-10\x20mg\x20IV\x202-6\x20saatte\x20bir;\x20önerilen\x20doz\x200.1\x20mg/kg\x20IV\x0a⚠\x20Solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:C'},{'ad':'muscoril','bilgi':'2\x20mL\x27lik\x20ampul\x20formunda\x20olup\x204\x20mg\x20tiyokolşikosid\x20içerir','doz':a0_0x508fef(0x1ef,'xhYR')},{'ad':['NaHCO3','Sodyum\x20Bikarbonat'],'bilgi':'✦\x20Hiperkalemi,\x20TCA\x20toksisitesi,\x20salisilat\x20toksititesi,\x20metabolik\x20asidoz.\x0a-\x20Serum\x20bikarbonatını\x20arttırır\x0a-\x201\x20ampul\x2010\x20ml\x20%8.4\x27lük\x20sodyum\x20bikarbonat\x2010\x20mEq\x20(10\x20mmol)\x20sodyum\x20bikarbonat\x20içerir.\x0a→\x20Hiperkalmi\x20veya\x20metabolik\x20asi→\x2050\x20mEq\x20IV\x20x\x201\x0aTCA\x20toksisitesi:\x201-2\x20mEq/kg\x20IV\x20bolus\x20pH\x207.45-7.55\x20arasında\x20tutacak\x20şekilde.\x0aSalisilat\x20toksisitesi:\x203\x20amp\x20(150mEq)\x201\x20litre\x20D5W\x20içinde\x20ilk\x20başta\x2010-20\x20ml/kg\x20bolus,\x20sonra\x202-3ml/kg/saat;\x20hedef\x20idrar\x20pH\x207.5-8.0\x0a⚠\x20KKY,\x20metabolik\x20alkaloza,\x20hipernatremi.\x20Gebelik\x20ktg:C','doz':'10amp\x20NaHCO3\x20IV\x20puşe'},{'ad':a0_0x508fef(0x1df,'Tacq'),'bilgi':'✦\x20Doğal\x20veya\x20sentetik\x20opiodlerin\x20etkilerini\x20geriye\x20döndürmek.\x0a-\x20Opiod\x20reseptörlerini\x20antagonize\x20eder.\x0a→\x200.4\x202\x20mg\x20IV/IM\x0a⚠\x20Allerji.\x20Gebelik\x20ktg:C'},{'ad':'Nitrogliserin','bilgi':'✦\x20KKY,\x20anjina,\x20HT\x0a-\x20venodilatatör,\x20cGMP\x20üretimini\x20stimüle\x20eder.\x0a→\x205-200mcg/dak,\x203-5dk\x20da\x20bir\x2010\x20mcg\x20etki\x20edene\x20kadar\x20arttırabilir.\x20Yüksek\x20dozlar\x20genellikle\x20pulmoner\x20ödemde\x20kullanılır.\x20Önerilen\x20başlama\x20dozu\x0a>5mcg/dak\x0a⚠\x20hipotansiyon,\x20methemoglebinemi.\x20Gebelik\x20ktg:C'},{'ad':a0_0x508fef(0x1e9,'@Fq*'),'bilgi':'✦\x20Hipertansif\x20acil\x0a-\x20direkt\x20vazodilatatör,\x20NO\x20serbestler\x0a→\x200.3\x20mcg/kg/dak\x20IV\x20başlanır\x2010\x20mcg/kg/dak\x20kadar\x20titre\x20edilir.\x20Maksimum\x20dozdan\x2010\x20dakika\x20sonra\x20kan\x20basıncı\x20hala\x20kontrol\x20altına\x20alınamadıysa\x20nitroprusid\x20kesilir.\x0a⚠\x20siyanid\x20toksisitesi,\x20hipotansiyon,\x20methemoglobinemi.\x20Gebelik\x20ktg:C'},{'ad':'Norepinefrin','bilgi':'✦\x20Sıvı\x20tedavisine\x20yanıtsız\x20hipotansiyon\x20(Şok\x20tablosu).\x0a-\x20alfa1\x20agonist\x20>\x20beta1\x20agonist\x0a→\x201-30\x20mcg/dak\x20IV\x0a⚠\x20taşidisritmi,\x20doku\x20nekrozu.\x0aGebelik\x20ktg:C'},{'ad':a0_0x508fef(0x1d2,'ynKD'),'bilgi':a0_0x508fef(0x1fb,'ADL*')},{'ad':a0_0x508fef(0x1c7,'Wu#r'),'bilgi':'✦\x20ajitasyon,\x20psikoz\x0a-\x20dopamin,\x20alfa\x201,\x20histamin\x20ve\x205HT2\x20reseptörlerini\x20antagonize\x20eder.\x0a→\x20:\x205-10mg\x20IM\x20(maksimum\x2030mg/gün)\x0a⚠\x20:\x20Demansa\x20bağlı\x20pskioz,\x20QT\x20uzaması,\x20Nöroleptik\x20maling\x20sendromu,\x20ektrapiramidal\x20yan\x20etki,\x20ortostatik\x20hipotansiyon,\x20IV\x20verilmemesi.\x20Gebelik\x20ktg:C'},{'ad':'Pantoprazol','bilgi':'✦\x20GÖR,\x20Erozif\x20özefajit,\x20ZollingerEllison\x20Sendrom,\x20GİS\x20kanama\x0a-\x20Proton\x20pompa\x20inhibitörü.\x0a→\x2040mg\x20PO\x0a⚠\x20Allerji.\x20Gebelik\x20ktg:B.'},{'ad':'pantpas','bilgi':'','doz':'1amp\x20pantpas\x20IV\x20puşe\x22'},{'ad':'parol','bilgi':'','doz':'1\x20flk\x20parol\x20IV\x2015dk\x20inf'},{'ad':'perlinganit','bilgi':'1\x20ampul\x20Perlinganitte®\x2010\x20mgr\x20gliserol\x20trinitrat\x20vardır.\x20İlacın\x20hazırlanışı\x20şu\x20şekildedir:\x20%\x200.9\x20NaCl\x20veya\x20%5\x20dekstroz\x20solusyonunda\x20çözülebilir.','doz':['1mp\x20perlinganit\x20100cc\x20SF:\x204cc\x20puşe,\x205cc/st\x20IV\x20inf']},{'ad':a0_0x508fef(0x1e0,'e*OD'),'bilgi':a0_0x508fef(0x1f0,'Ik]t')},{'ad':['plavix',a0_0x508fef(0x1c6,'M*TH')],'bilgi':'✦\x20AKS\x0a-\x20Trombosit\x20aktivasyonunu\x20engellemek\x20için\x20ADP\x20reseptörüne\x20irreversible\x20bağlanır.\x0a→\x2075-600\x20mg\x20PO\x0a⚠\x20Aktif\x20kanama,\x20alerjik\x20reaksiyonlar.\x20Gebelik\x20ktg:B.'},{'ad':'Pralidoksim\x20(PAM)','bilgi':'✦\x20antikolinesteraz\x20etkinliğe\x20sahip\x20olan\x20ajanlarla\x20zehirlenmelerde\x20(Organofosfat\x20intoksikasyonu).\x0a-\x20Kolinesterazı\x20yeniden\x20aktive\x20eder.\x0a→\x201-2\x20g\x20100\x20SF\x20içinde\x2015-30\x20dk\x0a⚠\x20Allerji.\x20Gebelik\x20ktg:C'},{'ad':'Prednizon','bilgi':'✦\x20Astım\x20atak,\x20alerjik\x20reaksiyonlar,\x20A-a\x20gradiyent\x20>35\x20veya\x20PaO2:<70mmHg’li\x20Pneumocystis\x20pnömonisi\x20(PCP\x20PNA)\x0a-\x20Çeşitli\x20glukokortikoid\x20ve\x20mineralokortikoid\x20etkiler\x20üretir.\x0a→\x201mg/kg/gün\x20PO\x0a⚠\x20İmmünsüpresyon,\x20GI\x20ülser/perforasyon,\x20hiperglisemi.\x20Gebelik\x20ktg:C'},{'ad':'prednol','bilgi':'250mg\x20metilprednizolon\x20içerir','doz':a0_0x508fef(0x1d3,'tvFy')},{'ad':a0_0x508fef(0x1cc,'QTS1'),'bilgi':'✦\x20prosedürel\x20sedasyon,\x20ventilatör\x20sedasyon,\x20RSI\x0a-\x20GABAa\x20agonisti,\x20Na\x20kanal\x20blokörü\x0a→\x20Prosedürel\x20Sedasyon:\x201\x20mg/kg\x20IV\x20bolus\x20sonra\x0a0.5\x20mg/kg\x20\x203\x20dakika\x20bir\x0aRSI\x20indüksiyonun:\x201.5-2.5\x20mg/kg\x20IV\x0aVentilator\x20Sedasyon:\x205-50\x20mcg/kg/dak\x0a⚠\x20hipotansiyon,\x20anaflaksi,\x20Bradikardi,\x20apne.\x20Gebelik\x20ktg:B'},{'ad':'Protamin\x20sülfat','bilgi':a0_0x508fef(0x1d9,'ADL*')},{'ad':a0_0x508fef(0x1dd,'^JhO'),'bilgi':'etken\x20maddesi\x20budesonid','doz':a0_0x508fef(0x1e3,'ynKD')},{'ad':a0_0x508fef(0x1d1,'p69X'),'bilgi':'✦\x20Aktif\x20ülser\x0a-\x20histamin\x20H2-reseptör\x20antagonisti\x0a→\x20150\x20-300\x20mg\x0a⚠\x20Allerji.\x20Gebelik\x20ktg:B'},{'ad':'Regüler\x20İnsülin','bilgi':'✦\x20Hiperkalemi,\x20DKA/Hiperglisemik\x20hiperosmalar\x20koma,\x20Kalsiyum\x20kanal\x20bloker\x20toksikasyonu\x0a-\x20Periferik\x20glukoz\x20alımını\x20arttırır,\x20potasyumu\x20intraselüler\x20alana\x20çeker,\x0a→\x0aHiperkalemi:\x205-10\x20unit\x20IV\x20x\x201.\x20DKA’da\x200.05-0.1ü/kg/saat\x0ainfüzyon.\x0aKKB\x20toksikasyonu:\x20Eğer\x20kan\x20şekeri\x20<250\x20mg/dL\x20ise\x2025\x20gram\x20dekstroz\x20ile\x20birlikte\x201\x20unit/kg\x20bolus\x20verilir;\x20Kan\x20şekerini\x20100200\x20mg/dL\x20arasında\x20tutacak\x20şekilde\x200.1\x20-1\x20ü/kg/saatten\x20dekstroz\x20ile\x20titre\x20edilir.\x0a⚠\x20hipokalemi,\x20hipoglisemi,\x20sadece\x20IV\x20yoldan\x20verilebilir.\x20Gebelik\x20ktg:B'},{'ad':'Rokuronyum','bilgi':'✦\x20Paralizan\x20olarak\x20RSI\x0a-\x20non-depolarizan\x20nöromüsküler\x20ajan\x0a→\x201mg/kg\x20IV\x0a⚠\x20uzamış\x20paralizi.\x20Gebelik\x20ktg:B'},{'ad':'Süksinilkolin','bilgi':'✦\x20RSI\x20paralize\x0a-\x20depolarizan\x20nöromüsküler\x20ajan\x0a→\x201.5\x20mg/kg\x20(veya\x203-4\x20mg/kg\x20IM)\x0a⚠\x20hiperkalemi,\x20hiperkalemi\x20ile\x20birlikte\x20subakut\x20yanık/ezilme,\x20glokom,\x20kafa\x20içi\x20basıncını\x20artırır.\x20Gebelik\x20ktg:C'},{'ad':['teobag','teofilin'],'bilgi':'TEOBAG\x20®\x20200\x20SOLÜSYON\x20200mg/100ml.\x20TEOBAG\x20®\x20400\x20SOLÜSYON\x20400mg/500ml.\x0aBronkodilatatör.\x20Genelde\x20diğer\x20ted.yanıtsız\x20hast.tercih\x20edilir.\x0aYetişkinde\x202x200-300mg.\x0a6\x20yaşından\x20büyük\x20çocuklarda:\x20Önerilen\x20doz\x202\x20x100-200\x20mg.\x0aGebelik\x20kategorisi\x20C.\x20Anne\x20sütüne\x20geçer.\x0a⚠\x20Kontrendikasyon;\x20aktif\x20peptik\x20ülser,\x20aşırı\x20duyarlılık.','doz':'teobag\x20200mg/100ml\x20IV\x20inf.'},{'ad':'tetanoz','bilgi':'','doz':[a0_0x508fef(0x1d6,'thPF'),a0_0x508fef(0x1f6,'pMEL'),'1\x20doz\x20tetanoz\x20aşısı\x20IM']},{'ad':'Ticagrelor','bilgi':'✦\x20AKS\x20(unstabil\x20anjina,\x20STEMI,\x20NSTEMI)\x0a-\x20Trombosit\x20aktivasyonunu\x20engellemek\x20için\x20ADP\x20reseptörüne\x20reversible\x20bağlanır.\x0a→\x20180\x20mg\x20yükleme\x20dozu,\x20sonrasında\x20günde\x202*90mg\x0a⚠\x20Geçirilmiş\x20İntrakraniyal\x20hemeroji,\x20aktif\x20kanama,\x20şiddetli\x20karaciğer\x20yetmezliği.\x20Gebelik\x20ktg:C'},{'ad':'Tiyopental','bilgi':'✦\x20RSI\x0a-\x20GABA’nın\x20reseptörlerinden\x20ayrılma\x20hızını\x20yavaşlatır.\x0a→\x2050-75\x20MG\x20IV\x20yavaş\x20puşe\x0a⚠\x20Astım,\x20akut\x20intermitan\x20porfiri,\x20.Gebelik\x20ktg:C'},{'ad':'transamin','bilgi':'Her\x20ampul\x20250\x20mg\x20traneksamikasit\x20içermelidir.','doz':a0_0x508fef(0x1d0,'i6#M')},{'ad':['ventolin','salbutamol','Albuterol'],'bilgi':'✦\x20Akut\x20bronkospazm,\x20hiperkalemi\x0a-\x20Selektif\x20beta\x202\x20agonisti\x0a→\x201\x20saat\x20içinde\x202,5-5mg\x2020\x20dakikada\x20bir.\x20Sonra\x20her\x201-4\x20saatte\x202,5-10\x20mg\x0a⚠\x20Taşikardi,\x20hiperglisemi,\x20hipokalemi.\x20Taşikardide\x20atrovent\x20tercih\x20et.\x20Gebelik\x20ktg:\x20C','doz':'1amp\x20ventolin\x20inh'},{'ad':'Verapamil','bilgi':'✦\x20Anjina\x20ve\x20aritmi\x0a-\x20Kalsiyum\x20kanal\x20blokörü.\x0a→\x20120\x20–\x20320\x20mg/gün.\x20SVT-HVYAF’de\x205-10\x20mg\x20IV.\x0a⚠\x20Sol\x20ventrikül\x20disfonksiyonu,\x20hipotansiyon,\x20hasta\x20sinüs\x20sendromu,\x202.\x20veya\x203.\x20derece\x20AV\x20blok.\x20Gebelik\x20ktg:C.'},{'ad':['zofran','Ondansetron'],'bilgi':a0_0x508fef(0x1d5,'O)5P'),'doz':a0_0x508fef(0x1e6,'aK!N')}];